From: An expanded biomarker panel for the detection of prostate cancer from urine DNA
Variable | Cases (n = 42) | Controls (n = 52) |
---|---|---|
Age | ||
n (%) | 42 (100.0%) | 50 (96.2%) |
Median | 66 | 64 |
Mean (SD) | 67.1 (7.1) | 63.9 (7.6) |
Range | 48–84 | 50–83 |
PSA | ||
n (%) | 40 (95%) | 51 (98.1%) |
Median | 6.4 | 5.2 |
Mean (SD) | 7.1 (3.3) | 5.6 (2.7) |
Range | 3.26–18.92 | 0.63–14.9 |
Race | ||
Alaskan Native | 1 (2.4%) | 0 (0.0%) |
Asian | 0 (0.0%) | 1 (1.9%) |
Black | 4 (9.5%) | 5 (9.6%) |
Hispanic | 1 (2.4%) | 1 (1.9%) |
White | 36 (85.7%) | 44 (84.6%) |
Missing | 0 (0.0%) | 1 (1.9%) |
Urine samples | ||
DRE and FV | 28 (66.7%) | 32 (61.5%) |
DRE only | 10 (23.8%) | 17 (32.7%) |
FV only | 4 (9.5%) | 3 (5.8%) |
Gleason score | ||
n | 39 (92.9%) | NA |
Mean (SD) | 7.1 (1.3) | |
≤ 7 | 26 (61.9%) | |
> 7 | 13 (30.9%) | |
Missing | 3 (7.1%) | |
Positive cores | ||
n | 39 (92.9%) | NA |
Mean (SD) | 4.2 (3.6) | |
≤ 3 | 19 (45.2%) | |
> 3 | 20 (47.6%) | |
Missing | 3 (7.1%) |